secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001213900-25-125418
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports FY 2025 net loss of $24.8M; launches LYMPHIR in U.S.
----------------------------------------------------------------------------

- Net loss of $24.8M ($0.34 per share) vs $21.1M ($0.31) in FY 2024, driven by pre-commercial investment.
- Cash and equivalents $3.9M as of Sep 30, 2025; raised $36M in three financings post- and intra-year.
- LYMPHIR launched in U.S. Dec 2025; distribution agreements with top three wholesalers secured.
- International access via Named Patient Programs in 19 markets; collaboration with Verix for AI-driven commercial targeting.
- R&D expense $6.4M (up from $4.9M); G&A $8.8M ($8.1M prior); stock-based comp $8.3M ($7.5M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/0001213900-25-125418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/ea0270775-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-125418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer